参考文献/References:
[1] Roth GA,Johnson C,Abajobir A,et al. Global,regional,and national burden of cardiovascular diseases for 10 causes,1990 to 2015 [J]. J Am Coll Cardiol,2017,70(1):1-25.
[2] 中国预防医学会,中华预防医学会心脏病预防与控制专业委员会,中华医学会糖尿病学分会,等.中国健康生活方式预防心血管代谢疾病指南[J]. 中华健康管理学杂志,2020,14(2): 113-134.
[3] 吴迪,张庆军. 中国冠心病诊疗现状和进展[J]. 中国研究型医院,2020,7(1): 71-75,192-197.
[4] Mehta A,Liu C,Nayak A,et al. Untargeted high-resolution plasma metabolomic profiling predicts outcomes in patients with coronary artery disease [J]. PLoS One,2020,15(8):e0237579.
[5] Jiang H,Jiang H,Zhang J,et al. The serum metabolic biomarkers in early diagnosis and risk stratification of acute coronary syndrome [J]. Front Physiol ,2020,11:776.
[6] Bai H,Sun K,Wu JH,et al. Proteomic and metabolomic characterization of cardiac tissue in acute myocardial ischemia injury rats[J]. PLoS One,2020,15(5): e0231797.
[7] Weckwerth W. Metabolomics in systems biology[J]. Annu Rev Plant Biol,2003,54:669-689.
[8] Nicholson JK,Lindon JC,Holmes E. ’Metabonomics’:understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica,1999,29(11):1181-1189.
[9] Fahy E,Subramaniam S. RefMet:a reference nomenclature for metabolomics[J]. Nat Methods,2020,17(12):1173-1174.
[10] Paynter NP,Balasubramanian R,Giulianini F,et al. Metabolic predictors of incident coronary heart disease in women[J]. Circulation,2018,137(8):841-853.
[11] Singh A. Tools for metabolomics[J]. Nat Methods,2020,17(1): 24.
[12] Puchades-Carrasco L,Palomino-Sch?tzlein M,Pérez-Rambla C,et al. Bioinformatics tools for the analysis of NMR metabolomics studies focused on the identification of clinically relevant biomarkers [J]. Brief Bioinform,2016,17(3):541-552.
[13] Kusonmano K,Vongsangnak W,Chumnanpuen P. Informatics for metabolomics[J]. Adv Exp Med Biol,2016,939:91-115.
[14] Hollywood KA,Schmidt K,Takano E,et al. Metabolomics tools for the synthetic biology of natural products [J]. Curr Opin Biotechnol,2018,54:114-120.
[15] Misra BB,Mohapatra S. Tools and resources for metabolomics research community:a 2017-2018 update[J]. Electrophoresis,2019,40(2):227-246.
[16] Misra BB. New tools and resources in metabolomics:2016-2017[J]. Electrophoresis,2018,39(7):909-923.
[17] Yu J,Jiang Y,Tu M,et al. Investigating prescriptions and mechanisms of acupuncture for chronic stable angina pectoris:an association rule mining and network analysis study [J]. Evid Based Complement Alternat Med,2020,2020:1931839.
[18] Alfaddagh A. Letter by alfaddagh regarding article,"healed plaques in patients with stable angina pectoris"[J]. Arterioscler Thromb Vasc Biol,2020,40(9):e256-e257.
[19] 赵娟,滕丽新,毛梅. 冠状动脉疾病的代谢组学特点及其诊断价值[J]. 中国循证心血管医学杂志,2017,9(9):1112-1117.
[20] Zhong Z,Liu J,Zhang Q,et al. Targeted metabolomic analysis of plasma metabolites in patients with coronary heart disease in southern China[J]. Medicine(Baltimore) ,2019,98(7):e14309.
[21] DeRatt BN,Ralat MA,Lysne V,et al. Metabolomic evaluation of the consequences of plasma cystathionine elevation in adults with stable angina pectoris[J]. J Nutr,2017,147(9):1658-1668.
[22] Long W,Liao H,Huang X,et al. Efficacy and safety of high-dose Xueshuantong injection (lyophilised) in reducing the incidence of major adverse cardiovascular events in patients with unstable angina:a protocol of a randomised,parallel-arm,controlled,double-blind and multicentre clinical trial based on dual antiplatelet therapy[J]. BMJ Open ,2020,10(8):e038074.
[23] Yu XH,Sun J,Wang Y,et al. Biomarkers of unstable angina pectoris and yangxin decoction intervention:an exploratory metabonomics study of blood plasma [J]. Medicine(Baltimore),2017,96(21):e6998.
[24] PouralijanAmiri M,Khoshkam M,Madadi R,et al. NMR-based plasma metabolic profiling in patients with unstable angina[J]. Iran J Basic Med Sci,2020,23(3):311-320.
[25] Liu Y,Li Y,Zhang T,et al. Analysis of biomarkers and metabolic pathways in patients with unstable angina based on ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry[J]. Mol Med Rep,2020,22(5):3862-3872.
[26] Wang J,Xu W,Zhao H,et al. Identification of potential plasma biomarkers and metabolic dysfunction for unstable angina pectoris and its complication based on global metabolomics[J]. Biosci Rep,2019,39(3):2019.
[27] Banks E,Welsh J,Joshy G,et al. Comparison of cardiovascular disease risk factors, assessment and management in men and women,including consideration of absolute risk:a nationally representative cross-sectional study [J]. BMJ Open,2020,10(12):e038761.
[28] Gundogdu G,Senol O,Demirkaya Miloglu F,et al. Serum metabolite profiling of ST-segment elevation myocardial infarction using liquid chromatography quadrupole time-of-flight mass spectrometry[J]. Biomed Chromatogr,2020,34(2):e4738.
[29] Goulart VAM,Santos AK,Sandrim VC,et al. Metabolic disturbances identified in plasma samples from ST-segment elevation myocardial infarction patients[J]. Dis Markers,2019,2019:7676189.
[30] Khan A,Choi Y,Back JH,et al. High-resolution metabolomics study revealing l-homocysteine sulfinic acid,cysteic acid, and carnitine as novel biomarkers for high acute myocardial infarction risk[J]. Metabolism,2020,104:154051.
[31] 许文轩,李彤,张磊等. 急性心肌梗死血浆标志代谢物及相关代谢通路的筛选[J]. 山东医药,2018,57(7):23-27.
[32] Khan A,Choi Y,Back JH,et al. High-resolution metabolomics study revealing L-homocysteine sulfinic acid,cysteic acid,and carnitine as novel biomarkers for high acute myocardial infarction risk[J]. Metabolism,2020,104:154051.
[33] Huang T,Zeleznik OA,Poole EM,et al. Habitual sleep quality,plasma metabolites and risk of coronary heart disease in post-menopausal women[J]. Int J Epidemiol,2019,48(4):1262-1274.
[34] Hartiala JA,Tang WH,Wang Z,et al. Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease[J]. Nat Commun,2016,7:10558.
[35] Tobias DK,Lawler PR,Harada PH,et al. Circulating branched-chain amino acids and incident cardiovascular disease in a prospective cohort of US women[J]. Circ Genom Precis Med,2018,11(4):e002157.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(9):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(9):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[4]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(9):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[5]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(9):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[6]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(9):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[7]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(9):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[8]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(9):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[9]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(9):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[10]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[11]王文杰 杨嘉馨 丁耀东 王可馨 牛佳龙 葛海龙.铁死亡在心血管疾病中的研究进展[J].心血管病学进展,2023,(5):420.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.009]
WANG Wenjie,YANG Jiaxin,DING Yaodong,et al.Ferroptosis in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(9):420.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.009]